171 related articles for article (PubMed ID: 23562906)
1. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Allard M; Khoudour N; Rousseau B; Joly C; Costentin C; Blanchet B; Tournigand C; Hulin A
J Pharm Biomed Anal; 2017 Aug; 142():42-48. PubMed ID: 28494338
[TBL] [Abstract][Full Text] [Related]
5. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
[TBL] [Abstract][Full Text] [Related]
6. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
[TBL] [Abstract][Full Text] [Related]
7. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Kralj E; Trontelj J; Pajič T; Kristl A
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
11. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
[TBL] [Abstract][Full Text] [Related]
12. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Hsieh Y; Galviz G; Zhou Q; Duncan C
Rapid Commun Mass Spectrom; 2009 May; 23(9):1364-70. PubMed ID: 19337981
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
[TBL] [Abstract][Full Text] [Related]
14. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
[TBL] [Abstract][Full Text] [Related]
15. [Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].
Wang J; Lü BH; Dai XJ; Zhang YF; Chen XY; Zhong DF
Yao Xue Xue Bao; 2017 Mar; 52(3):443-8. PubMed ID: 29979858
[TBL] [Abstract][Full Text] [Related]
16. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
17. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Roche S; McMahon G; Clynes M; O'Connor R
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117
[TBL] [Abstract][Full Text] [Related]
18. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
[TBL] [Abstract][Full Text] [Related]
19. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.
Zhang Y; Qiang S; Yu Z; Zhang W; Xu Z; Yang L; Wen A; Hang T
J Chromatogr Sci; 2014 Apr; 52(4):344-50. PubMed ID: 23574742
[TBL] [Abstract][Full Text] [Related]
20. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Bai F; Johnson J; Wang F; Yang L; Broniscer A; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2561-6. PubMed ID: 21803003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
